In order to control the COVID-19 pandemic, a policy for the diagnosis and screening of people likely to be infected with SARS-CoV-2 has been established The reference diagnostic test is RT-PCR on nasopharyngeal swab. Nasopharyngeal swabbing requires training, generates a risk of aerosolization and therefore viral transmission to the operator, and is unpleasant or even painful for the patient. RT-PCR is efficient, but time-consuming. It is therefore necessary to consider techniques that are less subject to difficulties of production and sampling, and less time-consuming. Tandem mass spectrometry on saliva samples is a promising option. A combined "mass spectrometry/saliva test" should provide faster results.
Diagnostic Test: Nasopharyngeal sampling
Swabs will be taken of nasopharyngeal samples for RT-PCR
Diagnostic Test: Saliva sampling
A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
Inclusion Criteria:
- The patient must not have opposed their inclusion in the study
- Patient presenting to the Walk-in Center for Emerging Biological Risks for SARS-CoV-2
screening by nasopharyngeal swab OR hospitalized in the Infectious and Tropical
Diseases Department for severe SARS-CoV-2 infection, diagnosed by RT-PCR on
nasopharyngeal sample, taken at Nîmes University Hospital, in the previous 24 hours.
Exclusion Criteria:
- Patient already included in the study
- The subject is in a period of exclusion determined by a previous study
- It is impossible to give the subject clear information
- The patient is under safeguard of justice or state guardianship
- Patient unable to give consent
CHU de Nîmes
Nîmes, France
Albert Sotto, Principal Investigator
Centre Hospitalier Universitaire de Nīmes